Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer

BMI-1, also known as a stem cell factor, is frequently upregulated in several malignancies. Elevated expression of BMI-1 correlates with poor prognosis and is therefore considered a viable therapeutic target in a number of malignancies including ovarian cancer. Realizing the immense pathologic significance of BMI-1, small-molecule inhibitors against BMI-1 are recently being developed. In this study, we functionally characterize PTC-028, an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification. We report that PTC-028 treatment selectively inhibits cancer cells in clonal growth and viability assays, whereas normal cells remain unaffected. Mechanistically, hyperphosphorylation-mediated depletion of cellular BMI-1 by PTC-028 coupled with a concurrent temporal decrease in ATP and a compromised mitochondrial redox balance potentiates caspase-dependent apoptosis. In vivo, orally administered PTC-028, as a single agent, exhibits significant antitumor activity comparable with the standard cisplatin/paclitaxel therapy in an orthotopic mouse model of ovarian cancer. Thus, PTC-028 has the potential to be used as an effective therapeutic agent in patients with epithelial ovarian cancer, where treatment options are limited. Mol Cancer Ther; 17(1); 39–49. ©2017 AACR.

[1]  Resham Bhattacharya,et al.  Inhibition of BMI1 induces autophagy-mediated necroptosis , 2016, Autophagy.

[2]  Resham Bhattacharya,et al.  Bmi-1: At the crossroads of physiological and pathological biology , 2015, Genes & diseases.

[3]  J. Chien,et al.  PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. , 2015, European journal of cancer.

[4]  P. Lagadec,et al.  The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells , 2015, Leukemia.

[5]  D Andrews,et al.  Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.

[6]  G. Washko,et al.  Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. , 2014, The Journal of clinical investigation.

[7]  A. Krešo,et al.  Self-renewal as a therapeutic target in human colorectal cancer , 2013, Nature Medicine.

[8]  Junying Yuan,et al.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death , 2013, Nature Reviews Molecular Cell Biology.

[9]  D. Rosen,et al.  Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications , 2012, Cell cycle.

[10]  A. Sood,et al.  Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer , 2011, PloS one.

[11]  Goberdhan P Dimri,et al.  The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors , 2010, Cell cycle.

[12]  George A Calin,et al.  MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. , 2009, Cancer research.

[13]  J. Marto,et al.  Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.

[14]  G. Bernier,et al.  BMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal , 2009, The Journal of Neuroscience.

[15]  In Hye Lee,et al.  Bmi1 regulates mitochondrial function and the DNA damage response pathway , 2009, Nature.

[16]  G. Prendergast,et al.  A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation , 2008, Oncogene.

[17]  Agnieszka Bronisz,et al.  Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. , 2008, Cancer research.

[18]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Hofer-Warbinek,et al.  XIAP regulates bi-phasic NF-kappaB induction involving physical interaction and ubiquitination of MEKK2. , 2008, Cellular signalling.

[20]  P. Vandenabeele,et al.  RIP1, a kinase on the crossroads of a cell's decision to live or die , 2007, Cell Death and Differentiation.

[21]  Yun-Fei Xia,et al.  Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. , 2006, Cancer research.

[22]  H. Ogura,et al.  Astroglial Trophic Support and Neuronal Cell Death , 2000, Journal of Neurochemistry.

[23]  Y. Lin,et al.  Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. , 1999, Genes & development.

[24]  J C Reed,et al.  Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases , 1999, The EMBO journal.

[25]  Christian Stehlik,et al.  Nuclear Factor (NF)-κB–regulated X-chromosome–linked iap Gene Expression Protects Endothelial Cells from Tumor Necrosis Factor α–induced Apoptosis , 1998, The Journal of experimental medicine.

[26]  Stefan Grimm,et al.  The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal , 1998 .

[27]  W. Lieberthal,et al.  Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. , 1998, American journal of physiology. Renal physiology.

[28]  Y. Tsujimoto.  Apoptosis and necrosis: Intracellular ATP level as a determinant for cell death modes , 1997, Cell Death and Differentiation.

[29]  Y. Tsujimoto,et al.  Intracellular ATP levels determine cell death fate by apoptosis or necrosis. , 1997, Cancer research.

[30]  B. Seed,et al.  RIP mediates tumor necrosis factor receptor 1 activation of NF‐kappaB but not Fas/APO‐1‐initiated apoptosis. , 1996, The EMBO journal.

[31]  D. Goeddel,et al.  TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. , 1996, Immunity.

[32]  A. Cossarizza,et al.  Control of apoptosis by the cellular ATP level , 1996, FEBS letters.

[33]  P. Leder,et al.  RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death , 1995, Cell.

[34]  A Hartley,et al.  Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease , 1994, Journal of neurochemistry.

[35]  W. Zong,et al.  Necrotic death as a cell fate. , 2006, Genes & development.

[36]  Z. Estrov,et al.  E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  P. Leder,et al.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. , 1998, Immunity.